| Metric | Q1 FY27 | Q4 FY26 | Q1 FY26 |
|---|---|---|---|
| Revenue from operations | 1626.0 | 1421.6 | 1302.7 |
| Other income | 70.9 | 61.4 | 26.3 |
| Total income | 1696.9 | 1483.1 | 1329.0 |
| Profit before exceptional items & tax | 446.8 | 347.1 | 331.1 |
| Profit before tax | 446.8 | 347.1 | 331.1 |
| Net profit | 334.2 | 266.7 | 255.3 |
| Operating margin | 26.3% | 23.4% | 24.9% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | +30.90% |
|---|---|
| Net profit, quarter on quarter | +25.30% |
| Revenue, year on year | +24.80% |
| Operating profit, year on year | +15.00% |
| Operating profit, quarter on quarter | +28.30% |
BSE results filing, NSE: AJANTPHARM. Figures extracted from the filing.
Ajanta Pharma Ltd: key numbers
- Share price
- ₹3,547.80
- Market cap
- ₹44,333 Cr
- Revenue (annual)
- ₹5,453 Cr
- Net profit (annual)
- ₹1,056 Cr
- P/E (TTM)
- 39.1×Sector 50.4×
- Promoter holding
- 63.48%-2.77% QoQ
- FII holding
- 7.68%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Ajanta Pharma Ltd
All →Ajanta Pharma Share Pledge
Aayush Agrawal (Trustee of Aayush Agrawal Trust) has released a pledge on 1,736,353 equity shares of Ajanta Pharma Limited. This follows loan repayment.
Ajanta Pharma Earnings Call Transcript: Key Takeaways
Ajanta Pharma reports strong Q1 FY27 results, but management remains cautious about sustainability, guiding for normalization in the US and acknowledging geopolitical headwinds in Asia.
- Call
- Guides 18% growth
Ajanta Pharma Earnings Call: Key Takeaways
Ajanta Pharma achieved record FY26 revenue >₹5,000cr and PAT >₹1,000cr, driven by strong US and Africa performance despite Asia supply chain headwinds.
Ajanta Pharma Earnings Call: Key Takeaways
Ajanta Pharma hit major milestones in FY26, surpassing ₹5,000cr revenue and ₹1,000cr PAT, but faces logistics-driven volatility in Asia and rising costs from Middle East conflicts.
Ajanta Pharma Q4 FY26 Results: Net Profit ₹266.7 Cr, Up 18.4% YoY
Ajanta Pharma Ltd reported revenue from operations of ₹1,422 Cr (+21.5% YoY) and net profit of ₹266.7 Cr (+18.4% YoY) for Q4 FY26.
- Key figure
- Net profit ₹266.7 Cr · +18.4% YoY